Stephen J. Schuster

About

Stephen J. Schuster, M.D., is the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma at the University of Pennsylvania. He serves as an Attending Physician in the Department of Medicine, Division of Hematology-Oncology at the Hospital of the University of Pennsylvania. Dr. Schuster is also the Director of Lymphoma Translational Research at the Abramson Cancer Center of the University of Pennsylvania. His research and clinical focus are centered on lymphoma, including chronic lymphocytic leukemia, and he is involved in clinical care and research related to these areas.

Research topics

• Medicine
• Internal medicine
• Immunology
• Mathematics
• Oncology
• Cancer research

Selected publications

• Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2021-09-10 · 556 citations

  article1st authorCorresponding
  PublisherDOI

• Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

  New England Journal of Medicine · 2021 · 509 citations

  BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. METHODS: We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients…

  DOI

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

  The Lancet · 2021-03-01 · 453 citations

  articleOpen access
  PublisherOA PDFDOI

• T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

  Nature Medicine · 2024 · 250 citations

  PublisherDOI

• Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2025-11-18 · 5 citations

  articleOpen accessSenior author

  We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JULIET trial (ClinicalTrials.gov identifier: NCT02445248), with a median follow-up of 74.3 months. The median duration of response (DOR) was not reached; the 60-month, relapse-free probability was 61% among responders. Higher relapse-free probability (DOR >70%) was observed in females and those with le…

  PublisherOA PDFDOI

Recent grants

• NIH Grant K08HL002167

  NIH · $358k · 1995

Frequent coauthors

• Sunita D. Nasta

  University of Pennsylvania

  604 shared

• Jakub Svoboda

  University of Pennsylvania

  540 shared

• Elise A. Chong

  Hospital of the University of Pennsylvania

  477 shared

• Daniel J. Landsburg

  407 shared

• Charalambos Andreadis

  University of California, San Francisco

  237 shared

• Stefan K. Barta

  225 shared

• Anthony R. Mato

  220 shared

• Marco Ruella

  University of Pennsylvania

  188 shared

Education

• MD

  Thomas Jefferson University Hospitals

• Medical Oncology Fellowship

  Pennsylvania Hospital

  1989

• Postdoctoral Research Fellowship (NIH Sponsored Individual NRSA), Cardeza Foundation for Hematologic Research

  Thomas Jefferson University Hospitals

  1988

• Cardeza Clinical and Research Fellow in Medicine (Hematology)

  Thomas Jefferson University Hospitals

  1988

• Medical Internship

  Pennsylvania Hospital

  1982

Similar researchers at University of Pennsylvania

• John Q. Trojanowskih-296
• Craig B. Thompsonh-277
• Daniel J Raderh-236